Viracta Therapeutics, Inc. (VIRX) Tops Q2 EPS by 12c
Tweet
Share
E-mailGet Alerts VIRX Hot Sheet
Join SI Premium – FREE
Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Alphabet to replace Verizon in the Dow Jones Industrial Average
- Enanta Pharma loses appeal in Pfizer Paxlovid patent case
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
